Circulating osteoprotegerin and receptor activator of NF-κB ligand system in patients with β-thalassemia major

Journal of Bone and Mineral Metabolism

Volumn 25, Issue 1, 2007, Pages 60-67

  Angelopoulos, Nicholas G ^a   Goula, Anastasia ^b   Katounda, Eugenia ^a   Rombopoulos, Grigorios ^a   Kaltzidou, Victoria ^a   Kaltsas, Dimitrios ^a   Malaktari, Sophia ^a   Athanasiou, Vassilis ^a   Tolis, George ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b Ag Sophia Children's Hospital   (Greece)

Author keywords

thalassemia; Bone turnover; OPG RANKL system; Osteoporosis

Indexed keywords

COLLAGEN TYPE 1; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CHELATION THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS LINKING; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TRANSFUSION;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHILD; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 33845798015     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-006-0728-6     Document Type: Article

References (37)

1. CE Jensen SM Tuck JE Agnew S Koneru RW Morris A Yardumian E Prescott AV Hoffbrand B Wonke 1998 High incidence of osteoporosis in thalassemia major J Pediatr Endocrinol Metab 11 975 977
2. A Lasco N Morabito A Gaudio M Buemi M Wasniewska N Frisina 2001 Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major Osteoporos Int 12 570 575
3. E Carmina G Di Fede N Napoli G Renda G Vitale C Lo Pinto D Bruno R Malizia GB Rini 2004 Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major Calcif Tissue Int 74 68 71
4. ML Anapliotou IT Kastanias P Psara EA Evangelou M Liparaki P Dimitriou 1995 The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches Clin Endocrinol 42 279 287
5. V De Sanctis A Pinamonti A Di Palma M Sprocati G Atti MR Gamberini C Vulo 1996 Growth and development in thalassemia major patients with severe bone lesions due to desferrioxamine Eur J Pediatr 155 368 371
6. E Voskaridou E Terpos 2004 New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia Br J Haematol 127 127 139
7. K Yano E Tsuda N Washida F Kobayashi M Goto A Harada K Ikeda K Higashio Y Yamada 1999 Immunological characterization of circulating osteoprotegerin/ osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis J Bone Miner Res 14 518 527
8. LC Hofbauer AE Heufelder 2000 Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases J Clin Endocrinol Metab 85 2355 2363
9. C Menaa SV Reddy N Kurihara H Maeda D Anderson T Cundy J Cornish FR Singer JM Bruder GD Roodman 2000 Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone J Clin Invest 105 1833 1838
10. DL Lacey E Timms HL Tan MJ Kelley CR Dunstan 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165 176
11. E Voskaridou E Terpos G Spina J Palermos A Rahemtulla A Loutradi D Loukopoulos 2003 Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia Br J Haematol 123 730 737
12. N Morabito A Gaudio A Lasco M Atteritano MA Pizzoleo M Cincotta M La Rosa R Guarino A Meo N Frisina 2004 Osteoprotegerin and RANKL in the pathogenesis of thalassemia induced osteoporosis: new pieces of the puzzle J Bone Miner Res 19 722 727
13. P Szulc LC Hofbauer AE Heufelder S Roth PD Delmas 2001 Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status J Clin Endocrinol Metab 86 3162 3165
14. S Khosla HM Arrighi LJ Melton EJ Atkinson WM O'Fallon C Dunstan BL Riggs 2002 Correlates of osteoprotegerin levels in women and men Osteoporos Int 13 394 399
15. H Isomura K Fujie K Shibata N Inoue T Iizuka G Takebe K Takahashi J Nishihira H Izumi W Sakamoto 2004 Bone metabolism and oxidative stress in postmenopausal rats with iron overload Toxicology 197 93 100
16. SW Fox SJ Haque AC Lovibond TJ Chambers 2003 The possible role of TGF-β-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro J Immunol 170 3679 3687
17. HM Massey J Scopes MA Horton AM Flanagan 2001 TGF-β stimulates the osteoclast-forming potential of peripheral blood hematopoietic precursors in a lymphocyte-rich microenvironment Bone (NY) 28 577 582
18. DT Denhardt M Noda 1998 Osteopontin expression and function: role in remodeling J Cell Biochem (Suppl) 30-31 92 102
19. N Yamamoto F Sakai S Kon J Morimoto C Kimura H Yamazaki I Okazaki N Seki T Fujii T Ueda 2003 Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis J Clin Invest 112 181 188
20. JM Liu HY Zhao G Ning YJ Zhao Y Chen Zh Zhang LH Sun MY Xu JL Chen 2005 Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75 Calcif Tissue Int 76 1 6
21. M Ziolkowska M Kurowska A Radzikowska 2002 High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor treatment Arthritis Rheum 46 1744 1753
22. F Buzi G Maccarinelli B Guaragni F Ruggeri G Radetti A Meini E Mazzolari D Cocchi 2004 Serum osteoprotegerin and receptor activator of nuclear factors κB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis Clin Endocrinol 60 87 91
23. L Alvarez P Peris N Guanabens S Vidal I Ros F Pons X Filella A Monegal J Munoz-Gomez AM Ballesta 2003 Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates Arthritis Rheum 48 824 828
24. HA Makhluf SM Mueller S Mizuno J Glowacki 2000 Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges Biochem Biophys Res Commun 268 669 672
25. WS Browner LY Lui SR Cummings 2001 Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women J Clin Endocrinol Metab 86 631 637
26. I Avbersek-Luznik BP Balon I Rus J Marc 2005 Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant 20 566 570
27. KW Oh EJ Rhee WY Lee SW Kim KH Baek MI Kang EJ Yun CY Park SH Ihm MG Choi HJ Yoo SW Park 2005 Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males Clin Endocrinol 62 92 98
28. A Fahrleitner-Pammer H Dobnig C Piswanger-Soelkner C Bonelli HP Dimai G Leb B Obermayer-Pietsch 2003 Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status Wien Klein Wochenschr 115 291 297
29. S Trofimov I Pantsulaia E Kobyliansky G Livshits 2004 Circulating levels of receptor activator of nuclear factor-κB ligand/osteoprotegerin/ macrophage-colony stimulating factor in a presumably healthy human population Eur J Endocrinol 150 305 311
30. R Hannon A Blumsohn K Naylor R Eastell 1998 Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability J Bone Miner Res 13 1124 1133
31. WS Simonet DL Lacey CR Dunstan M Kelley MS Chang 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 309 319
32. H Yasuda N Shima N Nakagawa SI Mochizuki K Yano N Fujise Y Sato M Goto K Yamaguchi M Kuriyama T Kanno A Murakami E Tsuda T Morinaga K Higashio 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 39 1329 1337
33. LC Hofbauer CR Dunstan TC Spelsberg BL Riggs S Khosla 1998 Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines Biochem Biophys Res Commun 250 776 781
34. LC Hofbauer M Schoppet P Schuller V Viereck M Christ 2004 Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women Clin Endocrinol 60 214 219
35. Q Chen H Kaji M Kanatani T Sugimoto K Chihara 2004 Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells Horm Metab Res 36 674 678
36. A Kusumi H Sakaki T Kusumi M Oda K Narita H Nakagawa K Kubota H Satoh H Kimura 2005 Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain J Bone Miner Metab 23 373 381
37. MP Whyte SE Obrecht PM Finnegan JL Jones MN Podgornik WH McAlister S Mumm 2002 Osteoprotegerin deficiency and juvenile Paget's disease N Engl J Med 347 175 184